# US 2017/0253586 A1 · Substituted Oxazole- and Thiazole-Based Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands II

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253586 A1
- Document ID: US20170253586A1
- Status: Published application
- Kind: A1
- Application number: 15/603,280
- Filed: 2017-05-23
- Published: 2017-09-07
- Earliest claimed: 2014-11-24
- Assignees: Medifron DBT Co., Ltd.
- Applicants: Medifron Dbt Inc.
- Inventors: Robert FRANK-FOLTYN; Christopher HABERMANN; Gregor BAHRENBERG; Bernhard LESCH; Nils DAMANN; Klaus SCHIENE; Hannelore STOCKHAUSEN; Thomas CHRISTOPH; Sven FRORMANN; Derek SAUNDERS; Jeewoo LEE
- Web page: https://patentgrep.com/patent/US20170253586A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 263/30: having two or three double bonds between ring members or between ring members and non-ring members
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

## Claims

### Claim 1

A substituted compound of general formula (I),
wherein
X represents O or S;
Y represents O, S or N—CN;
Z represents N(R3b) or C(R4aR4b);
R1 represents aryl or heteroaryl,
wherein said aryl or heteroaryl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of H, F, Cl, Br, CN, OH, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy; C1-4-alkoxy-C1-4-alkoxy; C1-4-alkylS(═O), hydroxy-C1-4-alkylS(═O), halo-C1-4-alkylS(═O), cyano-C1-4-alkylS(═O), C1-4-alkoxy-C1-4-alkylS(═O), C1-4-alkylS(═O)2, hydroxy-C1-4-alkylS(═O)2, halo-C1-4-alkylS(═O)2, cyano-C1-4-alkylS(═O)2, C1-4-alkoxy-C1-4-alkylS(═O)2, H2N, (C1-4-alkyl)(H)N, (hydroxy-C1-4-alkyl)(H)N, (halo-C1-4-alkyl)(H)N, (cyano-C1-4-alkyl)(H)N, (C1-4-alkoxy-C1-4-alkyl)(H)N, (C3-6-cycloalkyl)(H)N, (C3-7-heterocyclo-alkyl)(H)N, (C1-4-alkyl)2N, (hydroxy-C1-4-alkyl)(C1-4-alkyl)N, (halo-C1-4-alkyl)(C1-4-alkyl)N, (cyano-C1-4-alkyl)(C1-4-alkyl)N, (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)N, (C3-6-cycloalkyl)(C1-4-alkyl)N, (C3-7-heterocycloalkyl)(C1-4-alkyl)N, (hydroxy-C1-4-alkyl)2N, (C3-6-cyclo-alkyl)(hydroxy-C1-4-alkyl)N, (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)N,
R2 represents C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, C3-6-cycloalkyl or (C3-6-cycloalkyl)-C1-4-alkyl;
R3a and R3b each independently represent H, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl;
R4a and R4b each independently represent H, F, Cl, CN, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl; or
R4a and R4b together with the carbon atom connecting them form a C3-6-cycloalkyl or a C3-7-heterocycloalkyl; and
Ar represents aryl or heteroaryl,
wherein said aryl or heteroaryl may be condensed with an aromatic or aliphatic ring to form a bicycle,
and wherein said aryl or heteroaryl and said condensed aromatic or aliphatic ring each independently may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy, C1-4-alkoxy-C1-4-alkoxy, hydroxy-C1-4-alkoxy-C1-4-alkyl, C1-4-alkylS(═O), hydroxy-C1-4-alkylS(═O), halo-C1-4-alkylS(═O), cyano-C1-4-alkylS(═O), C1-4-alkoxy-C1-4-alkylS(═O), C1-4-alkylS(═O)2, hydroxy-C1-4-alkylS(═O)2, halo-C1-4-alkylS(═O)2, cyano-C1-4-alkylS(═O)2, C1-4-alkoxy-C1-4-alkylS(═O)2, C1-4-alkylS(═O)C1-4-alkyl, hydroxy-C1-4-alkylS(═O)C1-4-alkyl, C1-4-alkylS(═O)2C1-4-alkyl, hydroxy-C1-4-alkylS(═O)2C1-4-alkyl, H2N, (C1-4-alkyl)(H)N, (hydroxy-C1-4-alkyl)(H)N, (halo-C1-4-alkyl)(H)N, (cyano-C1-4-alkyl)(H)N, (C1-4-alkoxy-C1-4-alkyl)(H)N, (C3-6-cycloalkyl)(H)N, (C3-7-heterocycloalkyl)(H)N, (C1-4-alkyl)2N, (hydroxy-C1-4-alkyl)(C1-4-alkyl)N, (halo-C1-4-alkyl)(C1-4-alkyl)N, (cyano-C1-4-alkyl)(C1-4-alkyl)N, (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)N, (C3-6-cyclo-alkyl)(C1-4-alkyl)N, (C3-7-heterocycloalkyl)(C1-4-alkyl)N, (hydroxy-C1-4-alkyl)2N, (C3-6-cycloalkyl)(hydroxy-C1-4-alkyl)N, (C3-7-heterocycloalkyl)-(hydroxy-C1-4-alkyl)N, (H)2NC1-4-alkyl, [(C1-4-alkyl)(H)N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(H)N](C1-4-alkyl), [(halo-C1-4-alkyl)(H)N](C1-4-alkyl), [(cyano-C1-4-alkyl)(H)N](C1-4-alkyl), [(C1-4-alkoxy-C1-4-alkyl)(H)N](C1-4-alkyl), [(C3-6-cycloalkyl)(H)N](C1-4-alkyl), [(C3-7-heterocycloalkyl)-(H)N](C1-4-alkyl), [(C1-4-alkyl)2N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(halo-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(cyano-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C3-6-cycloalkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C3-7-heterocycloalkyl)(C1-4-alkyl)N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)2N](C1-4-alkyl), [(C3-6-cycloalkyl)(hydroxy-C1-4-alkyl)N](C1-4-alkyl), [(C3-7-hetero-cycloalkyl)(hydroxy-C1-4-alkyl)N](C1-4-alkyl), H2NC(═O), (C1-4-alkyl)(H)NC(═O), (hydroxy-C1-4-alkyl)(H)NC(═O), (halo-C1-4-alkyl)(H)N—C(═O), (cyano-C1-4-alkyl)(H)NC(═O), (C1-4-alkoxy-C1-4-alkyl)(H)—NC(═O), (C3-6-cycloalkyl)(H)NC(═O), (C3-7-heterocyclo-alkyl)(H)NC(═O), (C1-4-alkyl)2NC(═O), (hydroxy-C1-4-alkyl)(C1-4-alkyl)NC(═O), (halo-C1-4-alkyl)(C1-4-alkyl)NC(═O), (cyano-C1-4-alkyl)(C1-4-alkyl)NC(═O), (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)NC(═O), (C3-6-cyclo-alkyl)(C1-4-alkyl)NC(═O), (C3-7-heterocycloalkyl)(C1-4-alkyl)NC(═O), (hydroxy-C1-4-alkyl)2NC(═O), (C3-6-cycloalkyl)(hydroxy-C1-4-alkyl)NC(═O), (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)NC(═O), H2NS(═O)2, (C1-4-alkyl)(H)NS(═O)2, (hydroxy-C1-4-alkyl)(H)NS(═O)2, (halo-C1-4-alkyl)(H)NS(═O)2, (cyano-C1-4-alkyl)(H)NS(═O)2, (C1-4-alkoxy-C1-4-alkyl)(H)NS(═O)2, (C3-6-cycloalkyl)(H)N S(═O)2, (C3-7-heterocycloalkyl)(H)NS(═O)2, (C1-4-alkyl)2NS(═O)2, (hydroxy-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (halo-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (cyano-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (C3-6-cycloalkyl)(C1-4-alkyl)NS(═O)2, (C3-7-heterocyclo-alkyl)(C1-4-alkyl)NS(═O)2, (hydroxy-C1-4-alkyl)2NS(═O)2, (C3-6-cyclo-alkyl)(hydroxy-C1-4-alkyl)NS(═O)2, (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)NS(═O)2, H2NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)(H)NS(═O)2N(H)C1-4-alkyl, (hydroxy-C1-4-alkyl)(H)NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)2NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)S(═O)2N(H)C1-4-alkyl, (hydroxy-C1-4-alkyl)S(═O)2N(H)C1-4-alkyl, C3-6-cycloalkyl, (C3-6-cycloalkyl)-C1-4-alkyl, (C3-6-cycloalkyl)-C1-4-alkoxy, C3-7-hetero-cycloalkyl, (C3-7-heterocycloalkyl)-C1-4-alkyl, (C3-7-heterocycloalkyl)-C1-4-alkoxy,
wherein said C3-6-cycloalkyl or C3-7-heterocycloalkyl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from H, F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy;
aryl, heteroaryl, (aryl)C1-4-alkyl or (heteroaryl)C1-4-alkyl,
wherein said aryl or heteroaryl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of H, F, Cl, Br, CN, OH, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy;
optionally in the form of a single stereoisomer or a mixture of stereoisomers, in the form of the free compound and/or a physiologically acceptable salt or a solvate thereof.

### Claim 2 (depends on 1)

The substituted compound according to claim 1, wherein Y represents O.

### Claim 3 (depends on 1)

The substituted compound according to claim 1, wherein R3a represents H.

### Claim 4 (depends on 1)

The substituted compound according to claim 1, wherein
Z represents N(R3b), wherein R3b represents H; or
Z represents C(R4aR4b),
wherein R4a represents CH3 and R4b represents H or
wherein R4a and R4b each represent H.

### Claim 5 (depends on 1)

The substituted compound according to claim 1, wherein
R2 represents CH3, CFH2, CHF2, CF3, CH2CH3, CH(CH3)2 or C(CH3)3.

### Claim 6 (depends on 1)

The substituted compound according to claim 1, wherein
R1 represents
wherein
n is 0, 1, 2 or 3;
R5 represents F, Cl, Br, CN, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, and C1-4-alkoxy-C1-4-alkoxy
and
each R6 independently is selected from the group consisting of
F, Cl, Br, CN, OH, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy, C1-4-alkoxy-C1-4-alkoxy, C1-4-alkylS(═O), hydroxy-C1-4-alkylS(═O), C1-4-alkylS(═O)2, hydroxy-C1-4-alkylS(═O)2, H2N, (C1-4-alkyl)(H)N, (hydroxy-C1-4-alkyl)(H)N, (C1-4-alkyl)2N, (hydroxy-C1-4-alkyl)(C1-4-alkyl)N, (hydroxy-C1-4-alkyl)2N, [(C1-4-alkyl)(H)N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(H)N](C1-4-alkyl), [(C1-4-alkyl)2N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), H2NC(═O), (C1-4-alkyl)(H)NC(═O), (hydroxy-C1-4-alkyl)(H)NC(═O), (C1-4-alkyl)2NC(═O), (hydroxy-C1-4-alkyl)(C1-4-alkyl)NC(═O), (hydroxy-C1-4-alkyl)2NC(═O), H2NS(═O)2 (C1-4-alkyl)(H)NS(═O)2, (hydroxy-C1-4-alkyl)(H)NS(═O)2, (C1-4-alkyl)2NS(═O)2, (hydroxy-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (hydroxy-C1-4-alkyl)2NS(═O)2, C3-6-cycloalkyl, (C3-6-cycloalkyl)-C1-4-alkyl, (C3-6-cycloalkyl)-C1-4-alkoxy, C3-7-heterocycloalkyl, (C3-7-heterocycloalkyl)-C1-4-alkyl, (C3-7-heterocycloalkyl)-C1-4-alkoxy,
wherein said C3-6-cycloalkyl or C3-7-heterocycloalkyl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from H, F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy;
aryl, heteroaryl, (aryl)C1-4-alkyl or (heteroaryl)C1-4-alkyl,
wherein said aryl or heteroaryl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of H, F, Cl, Br, CN, OH, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy.

### Claim 7 (depends on 1)

The substituted compound according to claim 1, wherein the compound of general formula (I) has general formula (Ia)
wherein
X represents O or S;
Z represents N(R3b) or C(R4aR4b);
n is 0, 1 or 2;
R2 represents CH3, CFH2, CHF2, CF3, CH2CH3, CH(CH3)2 or C(CH3)3,
R3b independently represent H, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl or C1-4-alkoxy-C1-4-alkyl;
R4a and R4b each independently represent H, F, Cl or C1-4-alkyl;
R5 represents F, Cl, Br, CN, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, and C1-4-alkoxy-C1-4-alkoxy
and
each R6 independently is selected from the group consisting of F, Cl, Br, CN, OH, C1-4-alkyl, CF3, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy, C1-4-alkoxy-C1-4-alkoxy, C1-4-alkylS(═O), C1-4-alkylS(═O)2, H2N, (C1-4-alkyl)(H)N, (C1-4-alkyl)2N, H2NC(═O), (C1-4-alkyl)(H)NC(═O) and (C1-4-alkyl)2NC(═O);
and
Ar represents aryl or heteroaryl,
wherein said aryl or heteroaryl may be condensed with an aromatic or aliphatic ring to form a bicycle,
and wherein said aryl or heteroaryl and said condensed aromatic or aliphatic ring each independently may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy, C1-4-alkoxy-C1-4-alkoxy, hydroxy-C1-4-alkoxy-C1-4-alkyl, C1-4-alkylS(═O), hydroxy-C1-4-alkylS(═O), halo-C1-4-alkylS(═O), cyano-C1-4-alkylS(═O), C1-4-alkoxy-C1-4-alkylS(═O), C1-4-alkylS(═O)2, hydroxy-C1-4-alkylS(═O)2, halo-C1-4-alkylS(═O)2, cyano-C1-4-alkylS(═O)2, C1-4-alkoxy-C1-4-alkylS(═O)2, C1-4-alkylS(═O)C1-4-alkyl, hydroxy-C1-4-alkylS(═O)C1-4-alkyl, C1-4-alkylS(═O)2C1-4-alkyl, hydroxy-C1-4-alkylS(═O)2C1-4-alkyl, H2N, (C1-4-alkyl)(H)N, (hydroxy-C1-4-alkyl)(H)N, (halo-C1-4-alkyl)(H)N, (cyano-C1-4-alkyl)(H)N, (C1-4-alkoxy-C1-4-alkyl)(H)N, (C3-6-cycloalkyl)(H)N, (C3-7-heterocycloalkyl)(H)N, (C1-4-alkyl)2N, (hydroxy-C1-4-alkyl)(C1-4-alkyl)N, (halo-C1-4-alkyl)(C1-4-alkyl)N, (cyano-C1-4-alkyl)(C1-4-alkyl)N, (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)N, (C3-6-cycloalkyl)(C1-4-alkyl)N, (C3-7-heterocycloalkyl)(C1-4-alkyl)N, (hydroxy-C1-4-alkyl)2N, (C3-6-cyclo-alkyl)(hydroxy-C1-4-alkyl)N, (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)N, (H)2NC1-4-alkyl, [(C1-4-alkyl)(H)N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(H)N](C1-4-alkyl), [(halo-C1-4-alkyl)(H)N](C1-4-alkyl), [(cyano-C1-4-alkyl)(H)N](C1-4-alkyl), [(C1-4-alkoxy-C1-4-alkyl)(H)N](C1-4-alkyl), [(C3-6-cycloalkyl)(H)N](C1-4-alkyl), [(C3-7-heterocycloalkyl)(H)N](C1-4-alkyl), [(C1-4-alkyl)2N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(halo-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(cyano-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C3-6-cycloalkyl)(C1-4-alkyl)N](C1-4-alkyl), [(C3-7-heterocycloalkyl)(C1-4-alkyl)N](C1-4-alkyl), [(hydroxy-C1-4-alkyl)2N](C1-4-alkyl), [(C3-6-cyclo-alkyl)(hydroxy-C1-4-alkyl)N](C1-4-alkyl), [(C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)N](C1-4-alkyl), H2NC(═O), (C1-4-alkyl)(H)NC(═O), (hydroxy-C1-4-alkyl)(H)NC(═O), (halo-C1-4-alkyl)(H)NC(═O), (cyano-C1-4-alkyl)(H)NC(═O), (C1-4-alkoxy-C1-4-alkyl)(H)NC(═O), (C3-6-cycloalkyl)-(H)NC(═O), (C3-7-heterocycloalkyl)(H)NC(═O), (C1-4-alkyl)2NC(═O), (hydroxy-C1-4-alkyl)(C1-4-alkyl)NC(═O), (halo-C1-4-alkyl)(C1-4-alkyl)N—C(═O), (cyano-C1-4-alkyl)(C1-4-alkyl)NC(═O), (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)NC(═O), (C3-6-cycloalkyl)(C1-4-alkyl)NC(═O), (C3-7-heterocyclo-alkyl)(C1-4-alkyl)NC(═O), (hydroxy-C1-4-alkyl)2NC(═O), (C3-6-cycloalkyl)(hydroxy-C1-4-alkyl)NC(═O), (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)NC(═O), H2NS(═O)2, (C1-4-alkyl)(H)NS(═O)2, (hydroxy-C1-4-alkyl)(H)NS(═O)2, (halo-C1-4-alkyl)(H)NS(═O)2, (cyano-C1-4-alkyl)(H)N—S(═O)2, (C1-4-alkoxy-C1-4-alkyl)(H)NS(═O)2, (C3-6-cycloalkyl)(H)NS(═O)2, (C3-7-heterocycloalkyl)(H)NS(═O)2, (C1-4-alkyl)2NS(═O)2, (hydroxy-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (halo-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (cyano-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (C1-4-alkoxy-C1-4-alkyl)(C1-4-alkyl)NS(═O)2, (C3-6-cycloalkyl)(C1-4-alkyl)NS(═O)2, (C3-7-heterocyclo-alkyl)(C1-4-alkyl)NS(═O)2, (hydroxy-C1-4-alkyl)2NS(═O)2, (C3-6-cycloalkyl)(hydroxy-C1-4-alkyl)NS(═O)2, (C3-7-heterocycloalkyl)(hydroxy-C1-4-alkyl)NS(═O)2, H2NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)(H)N—S(═O)2N(H)C1-4-alkyl, (hydroxy-C1-4-alkyl)(H)NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)2NS(═O)2N(H)C1-4-alkyl, (C1-4-alkyl)S(═O)2N(H)C1-4-alkyl, (hydroxy-C1-4-alkyl)S(═O)2N(H)C1-4-alkyl, C3-6-cycloalkyl, (C3-6-cyclo-alkyl)-C1-4-alkyl, (C3-6-cycloalkyl)-C1-4-alkoxy, C3-7-heterocycloalkyl, (C3-7-heterocycloalkyl)-C1-4-alkyl, (C3-7-heterocycloalkyl)-C1-4-alkoxy,
wherein said C3-6-cycloalkyl or C3-7-heterocycloalkyl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from H, F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy;
aryl, heteroaryl, (aryl)C1-4-alkyl or (heteroaryl)C1-4-alkyl,
wherein said aryl or heteroaryl may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of H, F, Cl, Br, CN, OH, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, cyano-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, cyano-C1-4-alkoxy and C1-4-alkoxy-C1-4-alkoxy;
optionally in the form of a single stereoisomer or a mixture of stereoisomers, in the form of the free compound and/or a physiologically acceptable salt or a solvate thereof.

### Claim 8 (depends on 7)

The substituted compound according to claim 7, wherein n is 0.

### Claim 9 (depends on 1)

The substituted compound according to claim 1, wherein R5 is F, Cl, CN, CH3, CHF2, CF3, CH2CH3, OCH3, OCF3, OCHF2 or CH2OCH3.

### Claim 10 (depends on 1)

The substituted compound according to claim 1, wherein Ar is selected from phenyl or pyridinyl,
wherein said phenyl or pyridinyl may be condensed with an aromatic or aliphatic ring to form a bicycle, and
wherein said phenyl or pyridinyl and said condensed aromatic or aliphatic ring each independently may be unsubstituted or mono- or independently polysubstituted by one or more substituents, selected from the group consisting of F, Cl, Br, CN, OH, ═O, C1-4-alkyl, hydroxy-C1-4-alkyl, halo-C1-4-alkyl, C1-4-alkoxy-C1-4-alkyl, hydroxy-C1-4-alkoxy, halo-C1-4-alkoxy, C1-4-alkoxy-C1-4-alkoxy, H2N, (C1-4-alkyl)(H)N, (hydroxy-C1-4-alkyl)(H)N, H2NC(═O), (C1-4-alkyl)(H)NC(═O), (hydroxy-C1-4-alkyl)(H)NC(═O), (C1-4-alkyl)2NC(═O), (hydroxy-C1-4-alkyl)(C1-4-alkyl)NC(═O) and C3-6-cycloalkyl.

### Claim 11 (depends on 1)

The substituted compound according to claim 1, wherein Ar is selected from
each unsubstituted or mono- or independently polysubstituted by one or more substituents,
wherein said substituent(s) are selected from the group consisting of F, Cl, Br, CN, ═O, OH, CH3, CHF2, CF3, CH2CH3, (CH2)2CH3, CH(CH3)2, (CH2)3CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, C(CH3)3, OCH3, OCF3, OCHF2, CH2OCH3, CH2OCF3, CH2OH, CH2CH2OH, OCH2CH2OH, N(H)CH2CH2OH, N(CH3)CH2CH2OH, CH2OCH2CH2OH, CH2N(H)CH2CH2OH, CH2N(CH3)CH2CH2OH, CH2CH2S(═O)2CH3, CH2CH2S(═O)2N(H)CH3, CH2N(H)S(═O)2NH2, CH2N(H)S(═O)2CH3,

### Claim 12 (depends on 1)

The substituted compound according to claim 1, wherein Ar is selected from
wherein G is CH or CF.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising at least one substituted compound according to claim 1.

### Claim 14 (depends on 1)

A substituted compound according to claim 1 for use in the treatment and/or prophylaxis of one or more diseases and/or disorders selected from the group consisting of pain.

### Claim 15 (depends on 1)

A method of treatment and/or prophylaxis of disorders and/or diseases selected from the group consisting of pain in a mammal comprising administering an effective amount of at least one compound according to claim 1 to the mammal.

### Claim 16 (depends on 4)

The substituted compound according to claim 4, wherein Z represents N(R3b), wherein R3b represents H.

### Claim 17 (depends on 5)

The substituted compound according to claim 5, wherein R2 represents CF3 or C(CH3)3.

### Claim 18 (depends on 14)

The substituted compound according to claim 14, wherein the pain is selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain.

### Claim 19 (depends on 15)

The method according to claim 15, wherein the pain is selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain and joint pain.
